Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.

The urokinase-type plasminogen activator (uPA) system is a dynamic complex in which the membrane receptor uPAR binds uPA that binds the plasminogen activator inhibitor (PAI)-1 localized in the extracellular matrix, resulting in endocytosis of the whole complex by the low-density lipoprotein receptor-related protein (LRP). High expression of PAI-1 is paradoxically associated with marked tumor spreading and poor prognosis. We previously reported a nonproteolytic role of the [uPAR:uPA:PAI-1:LRP] complex operative in cell migration. Here we explored whether matrix PAI-1 could be used as a migration support by human breast cancer cells. We showed that the uPA system and LRP are localized at filopodia of invasive cells, and that formation/internalization of the [uPAR:uPA:PAI-1:LRP] complex is required for attachment and migration of cancer cells on plastic and on a PAI-1 coat. PAI-1 increased both filopodia formation and migration of cancer cells suggesting a chemokine-like activity. Migration velocity, expression of the uPA system, use of the [uPAR:uPA:PAI-1:LRP] complex to migrate, and promigratory effects of PAI-1 paralleled cancer cell invasiveness. Phenotyping and functional analysis of invasive cancer cell subclones indicated that different cell subpopulations may use different strategies to migrate depending on both the environment and their expression of the uPA system, some of them taking advantage of abundant available PAI-1.

[1]  F. Sánchez‐Madrid,et al.  Cytoskeletal rearrangement during migration and activation of T lymphocytes. , 1999, Trends in cell biology.

[2]  G. Vinson,et al.  In vitro regulation of human breast cancer cell adhesion and invasion via integrin receptors to the extracellular matrix , 1995, The British journal of surgery.

[3]  A. Gee,et al.  Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. , 1987, Journal of immunology.

[4]  E. Appella,et al.  Autocrine saturation of pro-urokinase receptors on human A431 cells , 1986, Cell.

[5]  P. Mignatti.  Extracellular matrix remodeling by metalloproteinases and plasminogen activators. , 1995, Kidney international. Supplement.

[6]  M. Berens,et al.  Substrates for astrocytoma invasion. , 1995, Neurosurgery.

[7]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[8]  D. Lawrence,et al.  Characterization of the Binding of Different Conformational Forms of Plasminogen Activator Inhibitor-1 to Vitronectin , 1997, The Journal of Biological Chemistry.

[9]  F. Sánchez‐Madrid,et al.  Polarization of Chemokine Receptors to the Leading Edge during Lymphocyte Chemotaxis , 1997, The Journal of experimental medicine.

[10]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[11]  M. Gyetko,et al.  The urokinase receptor is required for human monocyte chemotaxis in vitro. , 1994, The Journal of clinical investigation.

[12]  B. M. Mueller,et al.  Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system , 1997, International journal of cancer.

[13]  F. Sánchez‐Madrid,et al.  Leukocyte polarization in cell migration and immune interactions , 1999, The EMBO journal.

[14]  N. Brünner,et al.  Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. , 1995, Biological chemistry Hoppe-Seyler.

[15]  S. Moestrup,et al.  Immunohistochemical localization of urokinase‐type plasminogen activator, type‐1 plasminogen‐activator inhibitor, urokinase receptor and α2‐macroglobulin receptor in human breast carcinomas , 1996, International journal of cancer.

[16]  M. Delepierre,et al.  Stromal Cell-derived Factor-1α Associates with Heparan Sulfates through the First β-Strand of the Chemokine* , 1999, The Journal of Biological Chemistry.

[17]  S. Moestrup,et al.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.

[18]  E. Whitehorn,et al.  Receptor-mediated Endocytosis of CC-chemokines* , 1997, The Journal of Biological Chemistry.

[19]  D. Lauffenburger,et al.  Cell Migration: A Physically Integrated Molecular Process , 1996, Cell.

[20]  D. Loskutoff,et al.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? , 1996, The Journal of cell biology.

[21]  L. K. Rasmussen,et al.  Very low density lipoprotein receptor from mammary gland and mammary epithelial cell lines binds and mediates endocytosis of M r, 40,000 receptor associated protein , 1994, FEBS letters.

[22]  K. Preissner,et al.  Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. , 1997, Experimental cell research.

[23]  G. Nemerow,et al.  Urokinase Plasminogen Activator/Urokinase-specific Surface Receptor Expression and Matrix Invasion by Breast Cancer Cells Requires Constitutive p38α Mitogen-activated Protein Kinase Activity* , 2000, The Journal of Biological Chemistry.

[24]  Simi Ali,et al.  Examination of the Function of RANTES, MIP-1α, and MIP-1β following Interaction with Heparin-like Glycosaminoglycans* , 2000, The Journal of Biological Chemistry.

[25]  R. J. Rosser.  Consensus conference on the classification of ductal carcinoma in Situ , 1998, Cancer.

[26]  V. Tkachuk,et al.  The Chemotactic Action of Urokinase on Smooth Muscle Cells Is Dependent on Its Kringle Domain , 2000, The Journal of Biological Chemistry.

[27]  P. Carmeliet,et al.  Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. , 1998, Thrombosis research.

[28]  J W Sedat,et al.  Dynamics of a chemoattractant receptor in living neutrophils during chemotaxis. , 1999, Molecular biology of the cell.

[29]  J J Fredberg,et al.  Urokinase receptor mediates mechanical force transfer across the cell surface. , 1995, The American journal of physiology.

[30]  R. Alon,et al.  Real-time analysis of integrin-mediated chemotactic migration of T lymphocytes within 3-D extracellular matrix-like gels. , 1999, Journal of immunological methods.

[31]  S. Waxman,et al.  Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells , 1994, The Journal of cell biology.

[32]  Steingrimur Stefansson,et al.  The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin , 1996, Nature.

[33]  T. Hattori,et al.  Cellular localization of urokinase‐type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues , 1997, The Journal of pathology.

[34]  Y. Wei,et al.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. , 1997, The Journal of clinical investigation.

[35]  G. Barlovatz-Meimon,et al.  Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility. , 2000, Experimental cell research.

[36]  A. Villa,et al.  Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. , 1999, Blood.

[37]  S. Moestrup,et al.  Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. , 1993, The Journal of biological chemistry.

[38]  D. Ingber,et al.  Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. , 1997, Journal of cell science.

[39]  S. L. Gonias,et al.  Myosin Light Chain Kinase Functions Downstream of Ras/ERK to Promote Migration of Urokinase-Type Plasminogen Activator-Stimulated Cells in an Integrin-Selective Manner , 1999, The Journal of cell biology.

[40]  W. Fauquette,et al.  Characterization of morphogenetic and invasive abilities of human mammary epithelial cells: Correlation with variations of urokinase‐type plasminogen activator activity and type‐1 plasminogen activator inhibitor level , 1997, Biology of the cell.

[41]  D. Strickland,et al.  The Very Low Density Lipoprotein Receptor Mediates the Cellular Catabolism of Lipoprotein Lipase and Urokinase-Plasminogen Activator Inhibitor Type I Complexes (*) , 1995, The Journal of Biological Chemistry.

[42]  E. Kunkel,et al.  Integrating Conflicting Chemotactic Signals , 1999, The Journal of cell biology.

[43]  P. Andreasen,et al.  Very Low Density Lipoprotein Receptor Binds and Mediates Endocytosis of Urokinase-type Plasminogen Activator-Type-1 Plasminogen Activator Inhibitor Complex (*) , 1995, The Journal of Biological Chemistry.

[44]  J. Aguirre-Ghiso,et al.  Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. , 2000, Current opinion in cell biology.

[45]  M. Rothenberg,et al.  CC Chemokine Receptor-3 Undergoes Prolonged Ligand-induced Internalization* , 1999, The Journal of Biological Chemistry.

[46]  P. Jones,et al.  Regulation of urokinase receptor transcription by Ras- and Rho-family GTPases. , 2000, Biochemical and biophysical research communications.

[47]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[48]  K. Preissner,et al.  Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. , 1990, The Journal of biological chemistry.

[49]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[50]  C. Remacle,et al.  Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17β-estradiol, tamoxifen and ICI 182,780 , 1997, Clinical & Experimental Metastasis.

[51]  S. Muhammad,et al.  Plasminogen Activator Inhibitor-1 Contains a Cryptic High Affinity Binding Site for the Low Density Lipoprotein Receptor-related Protein* , 1998, The Journal of Biological Chemistry.

[52]  F. Blasi,et al.  Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes , 1997, The EMBO journal.

[53]  M. Mareel,et al.  Retinoic acid modulates both invasion and plasma membrane ruffling of MCF-7 human mammary carcinoma cells in vitro. , 1991, British Journal of Cancer.

[54]  N. Brünner,et al.  Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness , 1996, Clinical & Experimental Metastasis.